COVIDIG (COVID-19 Hyper-ImmunoGlobulin)

Study of Subcutaneous Immune Globulin in Patients Requiring IgG Replacement Therapy (Japan Study)

NCT01199705 ·Status: COMPLETED ·Phase: PHASE3

A Study to Assess the Tolerability and Safety of Subcutaneously (SC) Administered Immunoglobulin G (IgG) With Varying Injection Conditions

NCT07025577 ·Status: COMPLETED ·Phase: PHASE1

Multicenter Study of Long-Term Clinical Outcomes of Subcutaneous Immune Globulin IgPro20 in Subjects With Primary Immunodeficiency (Japan Study)

NCT01461018 ·Status: COMPLETED ·Phase: PHASE3

Specific IgG Antibody in Patients With Primary Antibody Deficiencies Treated With Subcutaneous Immunoglobulin

NCT00661401 ·Status: COMPLETED ·Phase: NA

Safety and Efficacy of IGIV 10% in Patients With Autoimmune Encephalitis:

NCT04175522 ·Status: COMPLETED ·Phase: PHASE2

Observational Study of Intranasal IVIG in Severe Acute Respiratory Syndrome Coronavirus 2 (SARS-CoV-2) Patients Undergoing Medical Tourism

NCT06992401 ·Status: NOT_YET_RECRUITING

To Evaluate the Clinical Efficacy of Iguratimod in the Treatment of IgG4 Related Disease (IgG4-RD) With Mild Symptom

NCT03368274 ·Status: UNKNOWN ·Phase: PHASE4

Efficacy and Safety of Intravenous Immunoglobulin IgPro10 in Patients With Primary Immunodeficiencies (PID)

NCT00168025 ·Status: COMPLETED ·Phase: PHASE3

Open Label Two-Arm Study to Evaluate Rilzabrutinib in IgG4-Related Disease Participants

NCT04520451 ·Status: COMPLETED ·Phase: PHASE2

The Efficacy and Safety of Iguratimod (IGU) in the Treatment of Primary Sjögren's Syndrome

NCT04981145 ·Status: RECRUITING ·Phase: PHASE4

Immunotherapy for Neurological Post-Acute Sequelae of SARS-CoV-2

NCT05350774 ·Status: ENROLLING_BY_INVITATION ·Phase: PHASE2

Study of ProMetic BioTherapeutics Immune Globulin Intravenous (Human) 10%

NCT02269163 ·Status: COMPLETED ·Phase: PHASE3

Treatment of Deficient Subclass or Anti-polysaccharide Antibody Response

NCT00522821 ·Status: COMPLETED ·Phase: PHASE4

An Open-label, Multicenter Study to Assess the Pharmacokinetics (PK), Safety, and Tolerability of Subcutaneous IgPro20 in Immunoglobulin (IG) Treatment-naïve Participants With Primary Immunodeficiency (PID)

NCT07076446 ·Status: ACTIVE_NOT_RECRUITING ·Phase: PHASE4

Good Use of Normal Human ImmunoGlobulins (NHIg): Feasibility of Integrating the Criteria of Hierarchy During of NHIg Dispensations

NCT06027450 ·Status: UNKNOWN

A Study Evaluating the Safety and Efficacy of Rituximab in Combination With Glucocorticoids in Participants With Wegener's Granulomatosis or Microscopic Polyangitis

NCT02115997 ·Status: COMPLETED ·Phase: PHASE4

Study to Evaluate the Efficacy and Safety of CM310 in Subjects With IgG4-related Disease

NCT05728684 ·Status: UNKNOWN ·Phase: NA

A Study of Inebilizumab Efficacy and Safety in IgG4- Related Disease

NCT04540497 ·Status: ACTIVE_NOT_RECRUITING ·Phase: PHASE3

Immunoglobulin G Therapy Dose Optimization

NCT04818177 ·Status: COMPLETED

Study to Evaluate the Effect of XmAb®5871 on Disease Activity in Patients With IgG4-Related Disease (RD)

NCT02725476 ·Status: COMPLETED ·Phase: PHASE2

A Study to Evaluate the Efficacy and Safety of IGIV-C in Symptomatic Subjects With Generalized Myasthenia Gravis

NCT02473952 ·Status: COMPLETED ·Phase: PHASE2

Comparison of the Efficacy and Safety of Immunoadsorption and Intravenous Immunoglobulin for Guillain-Barre Syndrome

NCT05114941 ·Status: NOT_YET_RECRUITING ·Phase: NA

Mini-pool Intravenous Immunoglobulin (MP-IVIG) in Guillain-Barré Syndrome

NCT04550611 ·Status: UNKNOWN ·Phase: NA

Study of the Efficacy and Safety of Intravenous Pamrevlumab, in Hospitalized Participants With Acute COVID-19 Disease

NCT04432298 ·Status: TERMINATED ·Phase: PHASE2

Safety and Tolerability of GX-P1 in Healthy Male Volunteers

NCT04298749 ·Status: COMPLETED ·Phase: PHASE1